Presenter: Michael Fossel, MD
Market/Indication: Biotech firm targeting Alzheimer’s disease, intending to begin FDA-sponsored human trials
Funding Stage: Seed
Development Stage: Pre-Clinical / Phase I
Location: United States
Telocyte™ focuses on curing Alzheimer’s disease. Telocyte™ plans to run FDA-sponsored human trials to reverse Alzheimer’s pathology at the cellular level. Currently, there are no effective medical or pharmaceutical interventions for those suffering from Alzheimer’s disease.
We have the technology (animal trials have already proven effective), the support, and the clinical experience to begin the first-in-human trials of an effective clinical cure for Alzheimer’s.